Identification of the Top 15 Drugs Associated With Anaphylaxis: A Pharmacovigilance Study
Clinical & Experimental Allergy · 2025
DOI: 10.1111/cea.70092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, 2025. Verfasst von Tae Hyeon Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea. Hauptthemen laut MEDLINE: Anaphylaxis, Pharmacovigilance, Drug Hypersensitivity, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Background
Drug‐associated anaphylaxis is a common condition with significant risks if not promptly addressed. Yet, systematic research on the distribution of associated drugs and risk comparison across drug classes is limited. This study aims to identify frequently reported drugs and evaluate the strength of their signal detections with drug‐associated anaphylaxis.
Methods
This study employed a global pharmacovigilance database to identify reports of drug‐associated anaphylaxis. Reports classified as anaphylaxis were analysed using the drug record number used in global pharmacovigilance database, leading to the identification of 15 frequently associated drugs. A disproportionality analysis was conducted to estimate signal detections between these selected drugs and anaphylaxis, utilising two metrics: the information component (IC) with a threshold of IC 0.25 and the reporting odds ratio (ROR) with 95% confidence intervals (CI). To account for the acute onset of anaphylaxis, a sensitivity analysis focused on reports with a time to onset of less than a day.
Results
We identified 15 drugs frequently associated with anaphylaxis, with diclofenac recording the highest number of reports at 34,413. The drug indicating the strongest signal detection with anaphylaxis was cefuroxime (ROR, 40.89 [95% CI, 40.18–41.61]; IC, 5.14 [IC 0.25 , 5.11]), followed by levofloxacin, ibuprofen, COVID‐19 vaccine, ceftriaxone, lidocaine, omalizumab, cefuroxime, benzylpenicillin, clindamycin, amoxicillin/clavulanate, cefazolin, ciprofloxacin, metronidazole, and paclitaxel. Sensitivity analysis indicated that the signal detection between the COVID‐19 vaccine and anaphylaxis was stronger than in the primary analysis (ROR, 2.49 [95% CI, 2.45–2.53]; IC, 1.23 [IC 0.25 , 1.21]). While most drugs reported that the majority of drug‐associated anaphylaxis reports occurred within 2.5 h, omalizumab was often associated with reactions occurring after 24 h.
Conclusion
All drugs frequently reported in association with anaphylaxis indicated a significant signal detection, but the strength of these signal detections did not align with the number of reports. Time‐to‐onset analysis showed distinct patterns for certain drugs, suggesting different mechanisms of anaphylaxis. Due to the limitations of spontaneous reporting databases with disproportionality analysis, our findings do not permit for causal inference.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
- Center for Digital Health, Medical Science Research Institute, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, Seoul, South Korea.
- Department of Precision Medicine, Kyung Hee University College of Medicine, Seoul, South Korea.
- Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.
- Department of Electronics and Information Convergence Engineering, Kyung Hee University, Yongin, South Korea.
- Centre for Health Performance and Wellbeing, Anglia Ruskin University, Cambridge, UK.
ORCID-Profile: Jaeyu Park, Hayeon Lee, Guillermo F López Sánchez, Yerin Hwang, Dong Keon Yon
Förderung
- Ministry of Science and ICT, South Korea
Zitieren
APA
Kim, T. H., Park, J., Jo, H., Oh, J., Lee, K., Oh, J., Lee, H., Smith, L., López Sánchez, G. F., Hwang, Y., & Yon, D. K. (2025). Identification of the Top 15 Drugs Associated With Anaphylaxis: A Pharmacovigilance Study. Clinical & Experimental Allergy. https://doi.org/10.1111/cea.70092
Vancouver
Kim TH, Park J, Jo H, Oh J, Lee K, Oh J, et al. Identification of the Top 15 Drugs Associated With Anaphylaxis: A Pharmacovigilance Study. Clinical & Experimental Allergy. 2025. doi:10.1111/cea.70092
BibTeX
@article{Kim2025,
author = {Kim, Tae Hyeon and Park, Jaeyu and Jo, Hyesu and Oh, Jeongseon and Lee, Kyeongmin and Oh, Jiyeon and Lee, Hayeon and Smith, Lee and López Sánchez, Guillermo F and Hwang, Yerin and Yon, Dong Keon},
title = {Identification of the Top 15 Drugs Associated With Anaphylaxis: A Pharmacovigilance Study},
journal = {Clinical & Experimental Allergy},
year = {2025},
doi = {10.1111/cea.70092}
}
EUVIMED